[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus
![[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2025%2F03%2Fclinical-trial-icon-gaac45ea20-1280.png&w=3840&q=75){kind=icon}
Atea Pharmaceuticals has launched a Phase 1 clinical trial for AT-587, an oral antiviral drug designed to treat hepatitis E. The study aims to assess the safety and pharmacokinetics of the drug in healthy volunteers.
Why it matters
Developing effective treatments for hepatitis E is critical for preventing chronic liver disease and failure in vulnerable populations.
Atea Pharmaceuticals, Inc. announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection.
AT-587 is a proprietary oral antiviral nucleotide analog being developed for the treatment of HEV, a potentially serious liver disease that can lead to chronic infection, cirrhosis and liver failure in certain patient populations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in